Abstract
A derivative spectrophotometric method for the determination of the antitumor agent cis-dichlorodiammineplatinum (II) in urine has been developed. The method is based on the complexation of cis-dichlorodiammineplatinum (II) with N, N'-bis (3-mercapto-2-quinoxalinyl)-1, 3-propanediamine. Optimum conditions for quantification of cis-dichlorodiammineplatinum (II) were established. The complex formed was stable in urine, and the recovery of platinum from urine was 92-95%. Interference arising from urine can be avoided by measurement of the second-order derivative spectrum. The relative standard deviations of the present method were 3.9% and 1.9% for the determination of 0.2 and 2.0 ppm of platinum in urine, respectively.
